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To evaluate the association between angiotensin I-converting enzyme insertion/deletion (ACE I/D) gene polymorphism
and retinal vein occlusion (RVO). A total of 80 patients with retinal vein occlusion who was admitted to the Eye
Department of Kartal Training and Research Hospital between 2008 and 2011, and 80 subjects were enrolled in this
retrospective case–control study. Patients who experienced RVO within one week to six months of study enrolment
were included, and those with coronary artery diseases, prior myocardial infarction history and coagulation disturbances
were excluded from the study. The diagnosis was made by ophthalmoscopic fundus examination and fluorescein
angiography. The ACE gene I/D polymorphism was determined by polymerase chain reaction, and the ACE gene was
classified into three types: I/I, I/D and D/D. In multivariate logistic regression analysis, ACE D/D genotype (p = 0.035),
diabetes-mellitus (p = 0.019) and hypertension (p = 0.001) were found to be independent predictive factors for RVO.
The results of the present study reveal that ACE D/D polymorphism is an independent predictive factor for RVO.
However, one cannot definitely conclude that ACE gene polymorphism is a risk factor for retinal vein occlusion.
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Angiotensin I-converting enzyme (ACE), dipeptidyl pep-
tidase, is a membrane-bound enzyme, which is present
in endothelial and epithelial cells of various tissues,
and innards including lungs and kidneys. Angiotensin
I-converting enzyme converts Angiotensin I to Angio-
tensin II, a very potent vasoconstrictor agent [1]. Angio-
tensin II is a hormone as well as a locally produced
cellular factor, directly affecting vascular endothelial cells
and smooth muscles [2]. Furthermore, it has been demon-
strated that receptors of Angiotensin II are found in the
atherosclerotic vessel walls [3]. It is pointed out that
Angiotensin II can promote vasoconstriction, inflamma-
tion and thrombosis in the vascular endothelium and
vessel walls [4]. Besides being a potent vasoconstrictor,
Angiotensin II is a proatherogenic agent, which elevates* Correspondence: bezgintahir3@yahoo.com
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unless otherwise stated.plasminogen activator inhibitor-1 (PAI-1) levels, which
results in a decrease in the fibrinolytic activity [5,6].
Previous studies have reported that plasma levels of
angiotensin II are closely associated with ACE inser-
tion/deletion (I/D) polymorphism and that the serum
level of ACE is likely to increase two-fold in the pres-
ence of ACE D/D polymorphism, consequently increas-
ing the levels of plasma angiotensin II [7]. It has also
been emphasized that the ACE I/D gene polymorphism
might be an independent risk factor for thrombotic dis-
eases [8-10].
There are very few studies examining the relationship
between ACE gene polymorphism and retinal vein throm-
bosis, with controversial results [11-14]. Therefore, we
aimed to evaluate the association between ACE I/D poly-
morphism and retinal vein occlusion (RVO).Methods
This case–control multi-center study composed of 80
patients, who experienced RVO one week to six months
before enrolment. Control group composed of age andal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Hardy-Weinberg Equilibrium Result
Genotype Expected Observed
Common homozygotes 37.13 38
Heterozygotes 34.74 33
Rare homozygotes 8.13 9
X2 = 0.2 (80 samples counted) for likelihoods of calculated X2 value see above.
p allele freq = 0.68; q allele freq = 0.32.
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other ocular diseases excluded with detailed ocular exam-
ination who referred to the eye clinic from internal me-
dicine clinics in which study conducted. Patients gave
written informed consent in accordance with the Declar-
ation of Helsinki. The Institutional Review Board of Kartal
Koşuyolu Heart Training and Research Hospital approved
the study.
Patients and controls
The patients with RVO and controls underwent a general
physical examination, and a thorough cardiovascular and
ophthalmic examination. A detailed medical history was
taken from the study cohort. We excluded the subjects
who had diabetic and/or hypertensive retinopathy findings
among the controls. This is because subjects having vas-
cular changing related to diabetes mellitus (DM) and/or
hypertension (HT) might cause confusion while being
evaluated the retinopathy related to RVO.
The diagnosis of RVO was made by ophthalmoscopic
fundus examination and flourescein angiography. On the
fundus examination, disc swelling, venous dilation or
tortuosity, retinal hemorrhages, cotton wool spots and
on the flourescein angiography demonstrating extensive
areas of capillary closure, venous filling defects and in-
creased venous transit time were assesed as the diagno-
sis of RVO by the same ophthalmologist.
The patients and controls were assessed for coagulation
abnormalities and thrombosis (antithrombin III, protein C
and protein S deficiency, lupus anticoagulant, anticardio-
lipin antibodies, activated protein C resistance, factor V
Leiden mutation, prothrombin 20210 mutation, mean
platelet volume, homocysteine, PAI-1 and lipoprotein A
levels).Patients with abnormalities in coagulation parame-
ters, previous thrombosis and family history of throm-
bosis, using oral contraceptives and hormone replacement
therapy, having renal and coronary artery diseases and a
prior history of myocardial infarction were excluded.
Hypercholesterolemia was defined as a total serum chol-
esterol level >200 mg/dL on admission or maintenance of
normal cholesterol levels with statin therapy. Hyperten-
sion was defined as a systolic blood pressure ≥140 mmHg
and a diastolic blood pressure ≥90 mmHg or current use
of antihypertensive medications. Patients on oral anti-
diabetic drug (OAD) therapy and/or insulin were consid-
ered as having diabetes.
Detection of ACE polymorphisms
Polymerase chain reaction (PCR)–cDNA coagulation
measures were performed to detect ACE polymorphisms
in cases with RVO and in controls. Blood samples were
taken from the antecubital vein after an overnight fast-
ing. Whole blood samples from the patients were col-
lected in ethylenediaminetetraacetic acid (EDTA) tubes.Total genomic DNA was isolated from whole blood sam-
ples using GenXtract DNA extraction system according
to the manufacturer’s instructions (Vienna Lab Diagnostic
GmbH). Then, target DNA regions were amplified by
multiplex polymerase chain reaction (PCR) using biotinyl-
ated primers. Thereafter, amplified products were sepa-
rated on 3% agarose gel. After observing the amplicons of
the related genes, the amplified products were hybridized
to a test strip containing allele specific nucleotide probes
immobilized on a nitrocellulose membrane, using Cardio-
vascular Disease (CVD) Strip Assay (Vienna Lab Diagnostic
GmbH). Hybridization process was performed with Tecan
Profiblot T48 hybridization device. Bound biotinylated se-
quences were detected using streptavidin-alkaline phos-
phatase and color substrates.
Angiotensin I-converting enzyme gene was classified as
I/I, I/D, D/D. The ACE gene I/D polymorphism was deter-
mined by PCR, using a primer pair flanking the poly-
morphic region of intron 16 that produces an amplified
490-bp (I allele), a 190-bp product (D allele) or both. All
the reactions were performed according to the method
by described previously [15]. The allele frequency was
confirmed according to Hardy-Weinberg equilibrium
(Table 1) [16].
Statistical analysis
Continuous variables were expressed as mean ± standard
deviation. Categorical variables were expressed as percent-
ages. The group means of continuous variables were com-
pared using an independent samples t-test. Categorical
variables were compared using the chi-square or the
Fisher’s exact tests. Multivariate logistic regression analysis
was applied to identify the independent predictors of RVO.
Variables which identified as significant in the univariate
analysis (diabetes mellitus, hypertension, hyperlipidemia,
current smoking, ACE D/D and I/D polymorphism) were
included in the model. Two-tailed p values <0.05 were
considered to indicate statistical significance. The Statistical
Package for the Social Sciences (SPSS, Inc., Chicago, IL,
USA) version 11.5 was used for all statistical analyses.
Results
This case–control study included 80 RVO patients (48.7%
males) with a mean age of 60.2 ± 12.1 years, and 80 con-
trols (47.5% males) with a mean age of 59 ± 12.6 years.
Baseline demographic characteristics of the patients and
Table 3 Angiotensin I-converting enzyme I/D gene
polymorphism in patients with RVO and control subjects
ACE Genotype RVO Control P value
II, n (%) 9 (11.3) 11 (13.8) 0.63
ID, n (%) 33 (41.3) 46 (57.5) 0.04
DD, n (%) 38 (47.5) 23 (28.8) 0.015
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tension (53.8 vs. 27.5%, p = 0.001), diabetes mellitus (38.8
vs. 15%, p = 0.001), hyperlipidemia (46.3 vs. 30.0%, p =
0.034 ) and current smoking (51.3 vs. 31.3%, p = 0.01) was
significantly much higher among patients with RVO, when
compared with that of controls. However, age, gender,
BMI and family history for CAD were similar between the
two groups (Table 2).
Angiotensin I-converting enzyme D/D gene polymorph-
ism was significantly higher in patients with RVO (47.5 vs.
28.8%, p = 0.015), while ACE I/D polymorphism was sig-
nificantly lower in patients with RVO than that of the con-
trols (41.3 vs. 57.5%, p = 0.04). However, with regard to
ACE I/I gene polymorphism, there was no significant dif-
ference between the two groups (11.3 vs. 13.8%, p = 0.63;
Table 3, Figure 1).
Frequency of ACE DD polymorphism in hypertensives
of control group was significantly lower compared to that
of patients with RVO ( 20.1 vs. 47.5%, p < 0.05), in contrast
ACE I/D polymorphism was significantly higher in hyper-
tensive controls than patients with RVO (65.8 vs. 41.3%,
p < 0.05). With regard to ACE I/I gene polymorphism,
there was no significant difference between the two groups
(11.3 vs. 14.1%, p =NS).
Frequency of ACE DD polymorphism in diabetics of
control group was significantly lower compared to that
of patients with RVO (23.8 vs. 47.5%, p < 0.05). ACE I/D
polymorphism was significantly higher in the diabetic
controls than patients with RVO (62.4 vs. 41.3%, p <
0.05). However, with regard to ACE I/I gene polymorph-
ism, there was no significant difference between the two
groups (11.3 vs. 13.4%, p = NS).
Angiotensin I-converting enzyme D/D genotype [Odds
Ratio (OR) = 3.83, 95% Confidence Interval (CI) = 1.10-
13.37, p = 0.035, diabetes mellitus (OR = 2.90, 95% CI =
1.19-7.09, p = 0.019) and hypertension (OR = 4.48, 95%Table 2 Baseline demographic characteristics of the RVO






Age (year) 60.2 ± 12.1 59 ± 12.6 0.54
Female (%) 41 (51.3) 42 (52.5) 0.87
Hypertension (%) 43 (53.8) 22 (27.5) 0.0001*
Diabetes mellitus (%) 31 (38.8) 12 (15.0) 0.001*
Hyperlipidemia (%) 37 (46.3) 24 (30.0) 0.034*
Current smoking (%) 41 (51.3) 25 (31.3) 0.01*
History for CAD (%) 23 (28.8) 17 (21.3) 0.27
BMI (kg/m2) 23.4 ± 3.1 23.8 ± 3.3 0.43
*p < 0.05.
Data are presented as mean ± standard deviation or number (%),
where appropriate.
RVO, retinal vein occlusion; CAD, coronary artery disease; BMI, body
mass index.CI 1.86-10.83, p = 0.001) were found to be the independ-
ent predictive factors for RVO in multivariate logistic re-
gression analysis.
Current smoking, hyperlipidemia and ACE I/D genotype
were the significant variables in the univariate analysis;
however, these parameters lost significance in multivariate
analysis (Table 4).
Discussion
The main finding of the present study is that ACE D/D
gene polymorphism is an independent predictive factor
for RVO. ACE I/D gene polymorphism was found to be
significantly lower in patients with RVO, when compared
with controls; however, ACE I/I polymorphism was similar
between the two groups.
Retinal vein occlusion is the second most common
retinal vascular disease after diabetic retinopathy in the
elderly. It leads to serious visual loss and blindness.
RVO is classified as central (CRVO) and branch RVO
(BRVO) depending on the site of occlusion. The preva-
lence of BRVO (0.6 - 1.6%) is greater than that of CRVO
(0.1 - 0.4%) [13,14]. The pathogenesis is multifactorial
and poorly understood. It has been assumed that ath-
erosclerotic vascular changes resulting in mechanical
compression of vessel walls and venous stasis, as well as
trophic changes in the endothelium, intima and media
layers of the veins are the main factors in the etiology of
RVO [17-19].
The potential risk factors related to RVO include age,
smoking, diabetes, hypertension, hyperlipidemia and
open-angle glaucoma [20-22]. In addition, compression of
the vein at the arteriovenous (A/V) crossing, degenerative
changes of the vessel wall and plasma abnormalities, in-
cluding resistance to activated protein C, deficiencies of
protein C, protein S, and antithrombin III, prothrombin
gene mutation, anti-phospholipid antibodies and hyperho-
mocysteinemia may be the other risk factors related to
RVO [23].
Angiotensin II promotes vasoconstriction, inflamma-
tion and thrombosis, and as a proatherogenic factor, de-
creases fibrinolytic activity via increasing PAI-1 levels.
Previous studies have shown that the plasma level of
angiotensin II is closely associated with ACE gene poly-
morphisms. ACE I/D gene polymorphism has been de-
scribed as an independent risk factor for thrombotic
diseases as well [8-10].
Figure 1 Comparison of frequencies of angiotensin I-converting enzyme I/D gene polymorphisms in patients with RVO vs. controls.
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ated ACE I/D gene polymorphism with diabetes mellitus
and hypertension, and stated that the results are specific
to the community studied, and ethnicity [24-27]. There-
fore, in order to identify ACE I/D gene polymorphism
as a predictor for RVO, ACE allele frequency in healthy
individuals and ACE gene polymorphism frequency in
patients with essential hypertension and type 2 dia-
betes mellitus should be considered in the population
studied [28,29].
In our study, the ACE D/D gene polymorphisms, dia-
betes mellitus, hypertension, hyperlipidemia, and smoking
were found to be significantly higher in the RVO group
compared to controls. Gori et al. [11] investigated whether
PAI 4G/5G and ACE I/D polymorphisms were independ-
ent risk factors for RVO and whether they were associated
with elevated PAI-1 activity levels. They demonstratedTable 4 Independent risk factors in terms of RVO-
multivariate analysis results
OR 95% CI P value
ACE DD genotype 3.83 1.10-13.37 0.035
Diabetes mellitus 2.90 1.19-7.09 0.019
Hypertension 4.48 1.86-10.83 0.001
Smoking 1.56 0.76-3.36 0.21
Hyperlipidemia 1.70 0.81-3.57 0.16
ACE ID genotype 0.62 0.18-2.01 0.44
OR = Odds ratio, CI = Confidence Interval.similar findings to our results that ACE D/D genotype is a
risk factor for RVO and confirmed the role of hypofibrino-
lysis, documented by high levels of PAI-1 activity, in pa-
tients with RVO. Yioti et al. [12] in a very recent study,
evaluated the polymorphisms related to thrombophilia/
hypofibrinolysis in a Greek population, and concluded that
there might be an association between increased risk for
RVO and ACE I/D, MTHFR C677T, PAI-1 4G/5G and
factor V Leiden polymorphisms. Although Sottilotta et al.
[13] reported hyperhomocysteinemia as a risk factor for
RVO but C677T MTHFR do not exist any association
with RVO in Italian population. In addition Glueck et al.
[14] demonstrated that factor V mutation, high levels of
heritable factor VIII, high homocysteine levels and low
levels of antithrombin III are associated with CRVO as a
familial thrombophlia. There were studies reporting find-
ings those are opposite to our study results [30]. Further-
more in a recent study an association among RVO and
ACE gen polymorphism was not demonstrated [31]. In
agreement with previous studies, ACE D/D gene poly-
morphism, diabetes mellitus and hypertension were found
to be the independent predictive factors for RVO. How-
ever, the association obtained between RVO and ACE I/D
gene polymorphism might be due to the association be-
tween ACE I/D gene polymorphism and diabetes mellitus
and/or hypertension. Therefore, in order to draw definite
conclusions, it is necessary to identify the frequency of
ACE gene polymorphism in patients with hypertension
and type 2 diabetes mellitus nation-wide. Compared to
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as a risk factor for RVO and other genetic factors includ-
ing factor V H1299R and V Leiden, β-fibrinogen G455A,
PAI-1 4G/5G, ACE I/D, HPA1, prothrombin G20210A,
factor XIII Val34Leu, MTHFR A1298C and C677T poly-
morphisms, activated protein C and S, antithrombin III
deficiency, antiphosolipid and anticardiolipin antibodies,
hyperhomocysteinemia may be possible other risk factors
and it is necessary to investigate these genetic factors for
RVO in large scale study groups .
As a result, in this study, the ACE D/D gene poly-
morphism was found to be an independent predictive
factor for RVO. However, it is difficult to say that this
polymorphism is a definite risk factor for RVO, due to
the scarcity of large-scale studies evaluating the distribu-
tion of ACE I/D gene polymorphism in patients with
diabetes mellitus and/or hypertension among Turkish
population. Therefore, studies performed on the rela-
tionship between RVO and ACE gene polymorphism
should take into consideration other systemic risk fac-
tors for RVO, keeping in mind that the results obtained
would be specific to the population studied. This will
yield more meaningful results that will help develop new
prophylactic and therapeutic strategies for the diagnosis,
treatment and follow-up of RVO.
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